Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV/hMPV vaccine in adults aged 60-75 years
NCT06583031Phase 1Completed
- Sponsor
- Sanofi
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SP0256 in respiratory syncytial virus infection (RSV) and human metapneumovirus infection (HMPV) (13 arms), sponsored by Sanofi. Primary endpoints: Unsolicited systemic Adverse Events within 30 minutes, Solicited injection site and systemic reactions at 7 days and 4 more. Started Oct 2024; status: completed.
02
Drugs
SP0256
03
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NCT06583031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06583031.